Hematologic Oncology

The European Commission has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.

Martin S. Tallman, MD, chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).

The FDA has approved midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed FLT3-positive acute myeloid leukemia in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The drug has also been approved for the treatment of patients with advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis, SM with associated hematological neoplasm, and mast cell leukemia.

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Ronald Go, MD, associate professor of Medicine, Mayo Clinic, discusses treatment for patients with thrombotic microangiopathy.

Achieving a complete response following ABVD chemotherapy offered the best chance for survival for patients with chronic lymphocytic leukemia who developed Hodgkin lymphoma following Richter transformation, according to a retrospective study published in the American Journal of Hematology.

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

Nathan Fowler, MD, discusses the current management of high-risk follicular lymphoma and ongoing developments in the field.

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Clara D. Bloomfield, MD, a groundbreaking researcher in adult leukemia and lymphoma who helped define new roles for women in science, was honored in the Myeloid Neoplasms category with a 2015 Giants of Cancer Care® award, a program that OncLive® developed to recognize leaders in the field.

Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies

A supplemental biologics license application has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma.

According to results from the phase II CHRONOS-1 trial, a majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib.

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

A biologics license application has been submitted for axicabtagene ciloleucel as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

The FDA has granted a priority review to a supplemental biologics license application supporting the conversion of the accelerated approval of blinatumomab to a full approval as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.